[go: up one dir, main page]

TR201900509T4 - Bir ilaç olarak kullanılmaya yönelik n-[2-(dietilamino)etil]-5-[(5-floro-1,2-dihidro-2-okso-3h-indol-3-iliden)metil]-2,4-dimetil-1h-pirol-3-karboksamidin l-malik asit tuzunu içeren bir kristal. - Google Patents

Bir ilaç olarak kullanılmaya yönelik n-[2-(dietilamino)etil]-5-[(5-floro-1,2-dihidro-2-okso-3h-indol-3-iliden)metil]-2,4-dimetil-1h-pirol-3-karboksamidin l-malik asit tuzunu içeren bir kristal. Download PDF

Info

Publication number
TR201900509T4
TR201900509T4 TR2019/00509T TR201900509T TR201900509T4 TR 201900509 T4 TR201900509 T4 TR 201900509T4 TR 2019/00509 T TR2019/00509 T TR 2019/00509T TR 201900509 T TR201900509 T TR 201900509T TR 201900509 T4 TR201900509 T4 TR 201900509T4
Authority
TR
Turkey
Prior art keywords
ylidene
indol
carboxamide
diethylamino
pyrrole
Prior art date
Application number
TR2019/00509T
Other languages
English (en)
Inventor
Hawley Michael
Thomas Fleck J
Stephen Prescott P
Mark Maloney T
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201900509(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of TR201900509T4 publication Critical patent/TR201900509T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Mevcut buluş, bir ilaç olarak kullanılmaya yönelik, N-[2-(dietilamino)etil]-5-[(5-floro-1,2-dihidro-2-okso-3H-indol-3-iliden)metil]-2,4-dimetil-1H-pirol-3-karboksamidin L-malik asit tuzunu içeren bir kristal sunar, buradaki kristal, bir toz X ışını kırınım deseninde 13.2 ve 24.2 derece iki tetada karakteristik kırınım piklerine sahiptir.
TR2019/00509T 2001-08-15 2002-08-13 Bir ilaç olarak kullanılmaya yönelik n-[2-(dietilamino)etil]-5-[(5-floro-1,2-dihidro-2-okso-3h-indol-3-iliden)metil]-2,4-dimetil-1h-pirol-3-karboksamidin l-malik asit tuzunu içeren bir kristal. TR201900509T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15

Publications (1)

Publication Number Publication Date
TR201900509T4 true TR201900509T4 (tr) 2019-02-21

Family

ID=23211067

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/00509T TR201900509T4 (tr) 2001-08-15 2002-08-13 Bir ilaç olarak kullanılmaya yönelik n-[2-(dietilamino)etil]-5-[(5-floro-1,2-dihidro-2-okso-3h-indol-3-iliden)metil]-2,4-dimetil-1h-pirol-3-karboksamidin l-malik asit tuzunu içeren bir kristal.

Country Status (42)

Country Link
US (2) US20030069298A1 (tr)
EP (3) EP2332934B1 (tr)
JP (1) JP4159988B2 (tr)
KR (1) KR100639281B1 (tr)
CN (2) CN100439360C (tr)
AP (1) AP1660A (tr)
AR (1) AR036261A1 (tr)
AU (1) AU2002324684B2 (tr)
BG (1) BG108553A (tr)
BR (1) BR0211612A (tr)
CA (1) CA2455050C (tr)
CO (1) CO5550431A2 (tr)
CU (1) CU23713B7 (tr)
CY (1) CY1121552T1 (tr)
CZ (1) CZ2004196A3 (tr)
DK (2) DK3168218T3 (tr)
EA (1) EA006445B9 (tr)
EC (1) ECSP044975A (tr)
ES (3) ES2453164T3 (tr)
GE (1) GEP20063777B (tr)
HR (1) HRP20040112B1 (tr)
HU (1) HU229206B1 (tr)
IL (1) IL160097A0 (tr)
IS (1) IS7147A (tr)
MA (1) MA27058A1 (tr)
ME (1) ME00414B (tr)
MX (1) MXPA04001452A (tr)
MY (1) MY139383A (tr)
NO (1) NO326508B1 (tr)
NZ (1) NZ531232A (tr)
OA (1) OA12650A (tr)
PL (1) PL216524B1 (tr)
PT (2) PT3168218T (tr)
RS (1) RS53251B (tr)
SI (2) SI1419151T1 (tr)
SK (1) SK902004A3 (tr)
TN (1) TNSN04028A1 (tr)
TR (1) TR201900509T4 (tr)
TW (1) TWI269796B (tr)
UA (1) UA76483C2 (tr)
WO (1) WO2003016305A1 (tr)
ZA (1) ZA200400706B (tr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332934B1 (en) 2001-08-15 2017-03-01 Pharmacia & Upjohn Company LLC Processes for the preparation of crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide.
HN2003000272A (es) * 2002-09-10 2008-07-29 Pharmacia Italia Spa Formulaciones que comprenden un compuesto de indolinona
BRPI0415022A (pt) * 2003-10-02 2006-11-28 Pharmacia & Upjohn Co Llc sais e polimorfos de um composto de indolinona substituìda com pirrol
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
DK1773811T3 (da) * 2004-07-22 2010-12-13 Lilly Co Eli Krystallinsk variabelt hydrat af (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amin)-2-methylpropyl)phenoxy)-3-pyridincarboxamid-hemisuccinatsalt
CA2603445A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
AU2006293644B2 (en) 2005-09-19 2012-05-31 Zoetis Services Llc Solid salt forms of a pyrrole substituted 2-indolinone
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
EP2220072A2 (en) * 2007-11-21 2010-08-25 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
US8389562B2 (en) * 2007-12-12 2013-03-05 Medichem, S.A. Polymorphic forms of a 3-pyrrole substituted 2-indolinone
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
CA2715657A1 (en) * 2008-02-21 2009-08-27 Generics (Uk) Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
JP2011516488A (ja) * 2008-03-31 2011-05-26 テバ ファーマシューティカル インダストリーズ リミティド スニチニブ及びその塩の調製方法
WO2009128083A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
WO2009140928A1 (zh) 2008-05-23 2009-11-26 上海医药工业研究院 二氢吲哚酮衍生物
AR072117A1 (es) * 2008-06-13 2010-08-04 Medichem Sa Procedimiento para preparar una sal de malato 3-pirrol sustituido 2-indolinona, intermediario de sintesis y una composicion farmaceutica que la comprende.
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
JP2011527330A (ja) * 2008-07-10 2011-10-27 ジェネリクス・（ユーケー）・リミテッド スニチニブリンゴ酸塩の結晶形の調製方法
KR20110036588A (ko) 2008-07-24 2011-04-07 테바 파마슈티컬 인더스트리즈 리미티드 수니티닙 아세테이트 및 이의 다형을 통한 수니티닙 말레이트의 제조 방법
WO2010010454A2 (en) 2008-07-24 2010-01-28 Medichem, S.A. Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
CA2734965A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel crystalline form and processes for its preparation
CN102197034A (zh) * 2008-08-25 2011-09-21 基因里克斯(英国)有限公司 舒尼替尼的新型多晶型物及其制备方法
CN102177155A (zh) * 2008-10-10 2011-09-07 麦迪凯姆股份公司 一种3-吡咯取代的2-吲哚酮苹果酸盐的制备工艺
EP2181991A1 (en) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2896618A1 (en) * 2009-01-02 2015-07-22 Hetero Research Foundation Polymorphs of sunitinib malate
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
US20120220783A1 (en) 2009-09-16 2012-08-30 Ranbaxy Laboratories Limited Salts of sunitinib
WO2011058521A2 (en) * 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
US8916716B2 (en) 2009-11-19 2014-12-23 Ranbaxy Laboratories Limited Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
WO2011092664A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
CA2792039A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
WO2011114246A1 (en) 2010-03-18 2011-09-22 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CA3019531A1 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2013140232A1 (en) 2012-03-23 2013-09-26 Laurus Labs Private Limited An improved process for the preparation of sunitinib and its acid addition salts thereof
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
EP2844282B1 (en) 2012-05-04 2019-06-12 Pfizer Inc Prostate-associated antigens and vaccine-based immunotherapy regimens
US9278955B2 (en) 2013-10-18 2016-03-08 Sun Pharmaceutical Industries Limited Ascorbic acid salt of sunitinib
CA2838587A1 (en) * 2013-10-18 2015-04-18 Hari Babu Matta Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation
DK3062815T3 (en) 2013-11-01 2019-03-11 Pfizer Vectors for expression of prostate-associated antigens
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
WO2020216450A1 (en) 2019-04-25 2020-10-29 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
JP2022529290A (ja) * 2019-04-18 2022-06-20 メーター ヘルス インコーポレイテッド 呼吸性不整脈を処置するための方法および組成物
JP7633786B2 (ja) 2020-09-18 2025-02-20 日本化薬株式会社 スニチニブリンゴ酸塩を有効成分とする医薬錠剤
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE157361T1 (de) 1990-10-15 1997-09-15 Pfizer Indolderivate
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
CZ282060B6 (cs) 1992-06-05 1997-05-14 Merck Sharp And Dohme Limited Sulfátová sůl substituovaného triazolu, způsob její výroby, farmaceutický prostředek s jejím obsahem a způsob jeho výroby
ZA941586B (en) * 1993-03-12 1995-09-07 Upjohn Co Crystalline ceftiofur free acid
US6329364B1 (en) 1994-08-31 2001-12-11 Eli Lilly And Company Crystalline form of dihydro-2,3-benzodiazepine derivative
DE19503966C2 (de) 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020038021A1 (en) 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en) 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US6066647A (en) 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
JP3631763B2 (ja) 1996-08-14 2005-03-23 ジー・ディー・サール・アンド・カンパニー ４―［５―メチル―３―フェニルイソキサゾル―４―イル］ベンゼンスルホンアミドの結晶形
KR100530601B1 (ko) 1996-12-25 2005-11-23 니폰 가야꾸 가부시끼가이샤 시스플라틴 미분말 및 그의 제조방법
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
EP1956014B1 (en) 1998-06-19 2019-01-16 Teijin Pharma Limited Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
JP2002532492A (ja) * 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー サイクリン−依存性キナーゼ、特にｃｄｋ２のインヒビターとしての４−アルケニル（及びアルキニル）オキシドール
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
AU1928501A (en) * 1999-11-24 2001-06-04 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
CO5280092A1 (es) 2000-02-15 2003-05-30 Sugen Inc Indolinas susutituidas con pirroles inhibidoras de proteinquinasas
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
EP2332934B1 (en) 2001-08-15 2017-03-01 Pharmacia & Upjohn Company LLC Processes for the preparation of crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide.
CA2715657A1 (en) 2008-02-21 2009-08-27 Generics (Uk) Limited Novel polymorphs and processes for their preparation
WO2009156837A2 (en) 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

Also Published As

Publication number Publication date
US20030069298A1 (en) 2003-04-10
ECSP044975A (es) 2004-03-23
CU23713B7 (es) 2011-10-05
EA006445B1 (ru) 2005-12-29
JP2005503386A (ja) 2005-02-03
DK3168218T3 (en) 2019-01-14
HRP20040112A2 (en) 2004-06-30
HK1088008A1 (zh) 2006-10-27
EP3168218B1 (en) 2018-11-14
NZ531232A (en) 2004-11-26
EP2332934A1 (en) 2011-06-15
CN100364991C (zh) 2008-01-30
KR20040030074A (ko) 2004-04-08
ES2623094T3 (es) 2017-07-10
NO326508B1 (no) 2008-12-15
CO5550431A2 (es) 2005-08-31
RS10304A (en) 2007-02-05
EA200400183A1 (ru) 2004-08-26
ES2705063T3 (es) 2019-03-21
EP3168218A1 (en) 2017-05-17
AP1660A (en) 2006-09-09
PL216524B1 (pl) 2014-04-30
MY139383A (en) 2009-09-30
BR0211612A (pt) 2004-08-24
US20070191458A1 (en) 2007-08-16
HK1066542A1 (en) 2005-03-24
MXPA04001452A (es) 2004-05-20
AR036261A1 (es) 2004-08-25
CN1543462A (zh) 2004-11-03
MA27058A1 (fr) 2004-12-20
SI1419151T1 (sl) 2014-04-30
PL368317A1 (en) 2005-03-21
IL160097A0 (en) 2004-06-20
CN1789264A (zh) 2006-06-21
EP1419151B1 (en) 2014-02-26
CZ2004196A3 (cs) 2005-01-12
ES2453164T3 (es) 2014-04-04
HRP20040112B1 (en) 2012-03-31
AU2002324684B2 (en) 2006-10-05
CA2455050C (en) 2007-02-20
AP2004002976A0 (en) 2004-03-31
NO20041054L (no) 2004-03-12
EP2332934B1 (en) 2017-03-01
CN100439360C (zh) 2008-12-03
CY1121552T1 (el) 2020-05-29
HU229206B1 (en) 2013-09-30
CA2455050A1 (en) 2003-02-27
PT3168218T (pt) 2019-01-11
WO2003016305A1 (en) 2003-02-27
US7435832B2 (en) 2008-10-14
ME00414B (me) 2011-10-10
HUP0700036A2 (en) 2008-10-28
PT1419151E (pt) 2014-03-27
RS53251B (sr) 2014-08-29
GEP20063777B (en) 2006-03-27
BG108553A (bg) 2005-04-30
TWI269796B (en) 2007-01-01
OA12650A (en) 2006-06-19
EA006445B9 (ru) 2017-02-28
DK1419151T3 (da) 2014-03-31
UA76483C2 (en) 2006-08-15
CU20040029A7 (es) 2008-03-14
SI3168218T1 (sl) 2019-05-31
ZA200400706B (en) 2005-05-25
EP1419151A1 (en) 2004-05-19
KR100639281B1 (ko) 2006-10-31
IS7147A (is) 2004-02-10
JP4159988B2 (ja) 2008-10-01
TNSN04028A1 (fr) 2006-06-01
SK902004A3 (sk) 2005-03-04

Similar Documents

Publication Publication Date Title
TR201900509T4 (tr) Bir ilaç olarak kullanılmaya yönelik n-[2-(dietilamino)etil]-5-[(5-floro-1,2-dihidro-2-okso-3h-indol-3-iliden)metil]-2,4-dimetil-1h-pirol-3-karboksamidin l-malik asit tuzunu içeren bir kristal.
NO2019005I1 (no) N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-1,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid (sunitinib), samt farmasøytisk akseptable salter
RU2350611C1 (ru) Производные фосфонооксихиназолина и их фармацевтическое применение
SE9103752D0 (sv) New compounds
SG164283A1 (en) New benzimidazole derivatives
BR9913899A (pt) Produto, medicamento, composição farmacêutica e utilização do produto
DK0711280T3 (da) Perhydroisoindolderivater, fremstilling af disse forbindelser og farmaceutiske præparater indeholdende disse forbindelser
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
NO20064288L (no) Tetraazabenzo(E)azulen-derivater og angaloger derav
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
TR200001872A2 (tr) 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine ilişkin yöntem.
BG100747A (en) INDOLE DERIVATIVES AS 5-HT1 agonists
NO944892L (no) N-substituerte 3-azabicyklo (3.2.0) hepatanderivater som neuroleptika osv.
DE69814612D1 (de) Stoffe zur hemmung der bildung des pterygiums und seines postoperative wiederauftretens
DE50209031D1 (de) Derivate des phenoxy-n-'4-(isothiazolidin-1,1-dioxid-2yl)phenyü-valerian-säureamids und andere verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen und tumoren
TNSN01034A1 (fr) Sel nouveau et formes polymorphes nouvelles de 4-amino-6, 7- dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydro-isoquinol-2-yl) - 5-(2-pyridyl)quinazoline
DE60112719D1 (de) Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterometrischen g proteinen in kombination mit einem antihypertensiven mittel zu einer therapeutischen verwendung in der behandlung von arterieller hypertonie
TH69655A (th) ผลึกซึ่งประกอบด้วยเกลือของกรดมาลิคของ 3-ไพร์รอล ซับสทิทิวเทด 2-อินโดลิโนน และสารผสมของสารเหล่านี้
TR200103169T2 (tr) 1,5-Benzodiazepin türevleri
ATE473216T1 (de) Hydroxymorpholinonderivat und dessen medizinische verwendung